Catalent Pharma Solutions, LLC (manufacturing bulk)

The drug is indicated for the treatment of adult men with metastatic hormone-sensitive prostate cancer (in combination with androgen deprivation therapy), as well as for the treatment of various forms of castration-resistant prostate cancer (both non-metastatic high-risk and metastatic).

Dosage form: capsules

ATC: L02BB04